Donate to Breastcancer.org when you checkout at Walgreens in October. Learn more about our Walgreens collaboration.

Enhertu Way More Effective Than Kadcyla as 2nd Tx for HER2+ MBC

Enhertu Dramatically More Effective Than Kadcyla as Second Treatment for Metastatic HER2-Positive Breast Cancer
September 22, 2021

Enhertu more than doubled the 12-month progression-free survival rate than Kadcyla in people diagnosed with metastatic HER2-positive breast cancer that had been previously treated. Read more...